Incannex commences dosing in phase 2 clinical trial assessing ihl-675a in patients with rheumatoid arthritis

Melbourne, australia and new york, jan. 24, 2024 (globe newswire) -- incannex healthcare inc. (nasdaq: ixhl), (‘incannex' or the ‘company'), a pharmaceutical company developing novel medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies for unmet medical needs, is pleased to announce that patient dosing has commenced in the phase 2 clinical trial assessing ihl-675a in patients with rheumatoid arthritis (ra).
IXHL Ratings Summary
IXHL Quant Ranking